Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Chloraseptic Max ads deemed too “strong”

This article was originally published in The Tan Sheet

Executive Summary

Prestige Brands should change marketing that touts its oral anesthetic products as "The strongest medicine you can get without a prescription," according to the National Advertising Division of the Council of Better Business Bureaus. Consumers could interpret the slogan used in broadcast and print insert ads for Chloraseptic Max lozenges and spray as a claim of superior pain relief, which "is unsupported by the evidence in the record," NAD said May 27. The spray product qualifies to bear a "maximum strength" claim since its 1.5 percent phenol formulation is the strongest allowed by FDA's monograph, but cannot imply superiority over other sore throat relief products, NAD said. Combe Inc., maker of competitor Cepacol, brought the challenge. Prestige said it plans to "adopt more traditional maximum strength parity claims in the future" and use different language to communicate the products' benefits. The Irvington, N.Y.-based firm previously said it is shifting marketing resources toward Chloraseptic and away from less-profitable brands (1"The Tan Sheet" March 16, 2009, p. 9)

You may also be interested in...



Prestige Brands Says Some OTC Brands Will Go, But Major Lines Will Stay

Prestige Brands looks to shed less profitable brands, including personal care products, and shift resources to Chloraseptic sore throat remedies and its other major OTC brands and household lines

Did Sarepta Need To Tell Investors About Its Vyondys 53 Dispute Resolution Request?

Attorneys say Sarepta did not have an obligation to report its appeal, particularly since winning a formal dispute filing with the US FDA is a long shot.

Sarepta’s Vyondys: Renal Toxicity Concerns That Delayed Approval Get Enhanced Postmarketing Scrutiny, Label Warning

Sarepta must perform enhanced pharmacovigilance for serious renal toxicity events and rhabdomyolysis with the Duchenne muscular dystrophy drug, which carries a label warning for renal toxicity. Approval letter includes 2024 target completion date for ESSENCE confirmatory trial.

Topics

UsernamePublicRestriction

Register

PS102961

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel